This initial presentation is intended to frame the session entitled 'Translating the Translational Sciences - Different Understanding, Common Aim 2.' Biomarkers and translational sciences drive progress and increase efficiency of drug development and medical practice. One notable challenge is distinguishing and implementing biomarkers versus clinical outcome assessments. This challenge is illustrated by recent examples in digital measurements in Parkinson's disease and functional status. Additional translational vignettes include surrogate endpoints and clinical outcome assessments, multi-component biomarkers, mechanism of action, translational clinical models, and reverse translation. Additional potential solutions are proposed for translational science challenges.
Learning Objectives:
Upon completion, participants will be able to distinguish advantages and disadvantages of invasive and non-invasive biomarker.
Upon completion, participants will be able to describe the use of biomarkers in clinical practise.
Upon completion, participants will be able to describe the use of PBPK modelling and virtual patients to assess biomarkers in a clinical setting.
